For Healthcare Professionals / Registered Medical Practitioners Only Login | Register

Blog on Fluid-Overload is out for the month of July 
Galaxy Bag Technology Added Benefits

HOW IS

FLEXBUMIN®

DIFFERENT

Description

FLEXBUMIN®
GALAXY® BAG
TECHNOLOGY

Used by health care professionals for the past 15 years, and thanks to its GALAXY technology, FLEXBUMIN® enables the use of a closed infusion system in albumin therapy.1-10

Description
Description

Available in different

Description
Description
NO SWABBING REQUIRED1-15
Description
NO OVERWRAP NEEDED1-15
Description
STERILE CLOSED INFUSION 
SYSTEM1-15
Description

USED BY HEALTHCARE PROFESSIONALS
FOR THE PAST 15+ YEARS

and thanks to its GALAXY technology FLEXBUMIN® enables the use of a closed infusion system in albumin therapy.1-10

 

REFERENCES

  1. Flexbumin® India Prescribing Information (PI).
  2. Four-layer bag technology - Ref-35896- Baxter - May 2017.
  3. Flexbumin® latex free statement-Internal Memo-January 2020.
  4. Analysis of Aluminum levels in Flexbumin® during stability - Internal Memo - July 2014.
  5. Efficiency Weights and Dimensions of Albumin vs. Flexbumin® - Internal Memo - 2017
  6. Maki DG, et al. Impact of Switching from an Open to a Closed Infusion System on Rates of Central Line-Associated Bloodstream Infection: A Meta-analysis of Time-Sequence Cohort Studies in 4 Countries. Infect Control Hosp Epidemiol 2011:32-50-58
  7. Carbon Trust Certification letter-Ref-38783-November 2014.
  8. Plasma Protein Therapeutics Association. Quality Standards of Excellence, Assurance and Leadership (QSEAL) Available at: https://www.pptaglobal.org/material/quality-standards-of-excellence-assurance-and-leadership-qseal Accessed May 2025.
  9. Baxalta US Inc. Flexbumin® 25%, Albumin (Human), USP, 25% Solution. Package insert. Jul 2017. Available at: https://www.shirecontent.com/PI/PDFS/FLEXBUMIN25_USA_ENG.pdf. Accessed November 2020.
  10. Baxalta US Inc. Flexbumin® 5%, Albumin (Human) USP, 5% Solution. Package insert. July 2017. Available at: https://www.shirecontent.com/PI/PDFS/FLEXBUMINS USA ENG.adf. Accessed November 2020.
  11. Štrbová P, et al. Residual volumes and final weights in different types of plastic infusion containers. Int J Pharm Sci. 2016:8(3):293-296.
  12. Summary Report of Observations for Flexbumin® bags and Buminate bottles. Shire, Data on file-ID: FLEX-005. July 2017.
  13. Albumin packaged as Flexbumin® and BUMINATE. Baxter Healthcare Corporation. Data on file. 2012.
  14. Disposal cost assessment. Baxter Healthcare Corporation. Data on file, ref-34896. April 2010.
  15. DOW. Saran PVDC Resins & Films and the Environment, DOW Form No. 190-00500-0305 March 2005

Therapeutic Indication: Restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is approprite.
The choice of albumin rather then artificial colloid will depend on the clinical situation of the individual patient, based on official recommendations.

This website is intended to provide information to Healthcare Professionals and/or Registered Medical Practitioners only; it should not be used for diagnosing or treating a health problem or disease. Healthcare professionals and registered medical practitioners shall apply their independent medical judgment and patient analysis for assessing any patient and not rely on the material provided on this Website. It contains information on FLEXBUMIN®, which is based on the India Prescribing Information (PI). This website has been developed by Takeda in accordance with industry and legal standards about FLEXBUMIN®. Takeda makes every reasonable effort to include accurate and current information. However, the information provided on the website is not exhaustive. This website is not intended to be used to report adverse events or product quality complaints. If you would like to report an adverse event or product quality complaint, please contact us at AE.India@takeda.com.

This information is solely intended for the use of Registered Medical Practitioner and Hospital only. This information should not be used or shared or distributed to any other person/party and should be strictly by the intended parties for the intended purposes only.For more information please refer to full Prescribing Information

This material contains copyright protected information, content; the use of which is limited by law and this material cannot be reproduced,replicated, used or modified by any person for their own use or further distribution.

FLEXBUMIN® is trademark or registered trademark of Baxalta Incorporated. TAKEDA and the TAKEDA logo are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited.

C-APROM/IN/FLEX/0286
Preparation Date: 27/May/2025

Takeda
Copyright ©2025 Takeda Pharmaceutical Company Limited. All rights reserved.

Privacy Policy

Terms of Use

Prescribing Information

Safety Information

Contact